REVOLADE works at the source of the disease

REVOLADE: Proven to overcome challenges with IST in first-line SAA1,9

  • In SAA, high levels of interferon-gamma inhibit TPO signaling that is essential for the maintenance and differentiation of hematopoietic stem and multipotent progenitor cells2

  • REVOLADE uniquely binds to the transmembrane domain of the TPO receptor and has been shown to bypass this inhibition1,9

    • By not competing with endogenous TPO, REVOLADE promotes stem-cell survival and differentiation, and neutrophil, erythrocyte, and platelet production9

EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor;
IST, immunosuppressive therapy; SAA, severe aplastic anemia; TPO, thrombopoietin.